Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd
(MedPage Today) -- The FDA announced a voluntary recall of an over-the-counter glucose support supplement for the presence of metformin and glyburide.
Over the past two decades, the prevalence of diabetes and obesity, respectively, increased from... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - November 21, 2023 Category: Endocrinology Source Type: news
Bonsity (Teriparatide Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2021 Category: Drugs & Pharmacology Source Type: news
Increlex (mecasermin [rDNA origin])
Title: Increlex (mecasermin [rDNA origin])Category: MedicationsCreated: 6/15/2021 12:00:00 AMLast Editorial Review: 6/15/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 15, 2021 Category: Drugs & Pharmacology Source Type: news
Sequential IV Ibandronate Tied to BMD Increase Sequential IV Ibandronate Tied to BMD Increase
Monthly intravenous ibandronate is associated with increases in bone mineral density and bone microstructure benefits in women with osteoporosis after teriparatide treatment, according to new findings.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 9, 2020 Category: Orthopaedics Tags: Rheumatology News Source Type: news
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry
Generics - User Fees (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Bonsity (Teriparatide Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 9, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Approves Bonsity (teriparatide injection) to Treat Osteoporosis
SAN DIEGO, October 7, 2019— Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for Bonsity (PF708) submitted under the 505(b)(2)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 7, 2019 Category: Drugs & Pharmacology Source Type: news
High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier
The combination of high-dose teriparatide with denosumab could represent an ideal intervention for postmenopausal women with osteoporosis at very high risk of fracture; cost is a concern, however.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - August 29, 2019 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Richter Launched Terrosa(R), its Biosimilar Teriparatide Across Europe
BUDAPEST, Hungary, Aug. 20, 2019 -- (Healthcare Sales & Marketing Network) -- Gedeon Richter Plc. ("Richter") today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the sam... Biopharmaceuticals, Product Launch Gedeon Richter, biosimilar, teriparatide, Terrosa, Forsteo, osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 20, 2019 Category: Pharmaceuticals Source Type: news
Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates Osteoporosis Dilemma: Denosumab or Teriparatide After Bisphosphonates
For osteoporosis patients on bisphosphonates for more than a year, switching to teriparatide rather than denosumab should be done with caution, especially for those at high risk of hip fracture, although denosumab has risks of its own, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
How Can Nanotechnologies Aid Implantable Drug-Delivery Systems?
Implantable technologies have come a long way over the years, and advancements in micro and nanotechnologies have helped device developers continue to push the envelope even further. Within the realm of drug delivery, advances in nanotechnologies have consistently improved patient outcomes by enabling sustained drug delivery to help treat chronic conditions. These scalable technologies have even offered localized drug delivery that can further improve bioavailability.
While many of these technologies offer a variety of opportunities, we’re still eagerly awaiting to see the impact of these advancements onc...
Source: MDDI - November 29, 2018 Category: Medical Devices Authors: Kristopher Sturgis Tags: BIOMEDevice San Jose Implants Source Type: news
ASBMR: High-Dose Forteo Plus Prolia Increased BMD
(MedPage Today) -- Responses greater than what was seen with either drug alone in high-risk women (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 2, 2018 Category: Endocrinology Source Type: news
Apidra (Insulin Glulisine [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 20, 2018 Category: Drugs & Pharmacology Source Type: news
GlucaGen (Glucagon [rDNA origin]) for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 17, 2018 Category: Drugs & Pharmacology Source Type: news
Fortical (Calcitonin-Salmon (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 2, 2018 Category: Drugs & Pharmacology Source Type: news
